Director Fabrice Egros resigns from Syndax board; Dennis Podlesak joins Audit Committee

Syndax Pharmaceuticals Inc

Fabrice Egros resigned from Syndax board effective Feb 23, 2022 due to expanded role at Lupin Limited.
Resignation not due to any disagreement with the company on operations, policies, or practices.
Board appointed Dennis G. Podlesak to the Audit Committee following Egros' departure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fabrice Egros

Director

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-02-23
Filed: February 24, 2022, 6:59 PM ET

On February 22, 2022, Fabrice Egros, PharmD, Ph.D. notified Syndax Pharmaceuticals, Inc. (the "Company") of his decision to resign from the Board of Directors of the Company (the "Board") due to an increase in the scope of his role at Lupin Limited.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fabrice Egros resigned as Director at Syndax Pharmaceuticals Inc.

Action: resigned
Role: Director

Exact text from the filing

On February 22, 2022, Fabrice Egros, PharmD, Ph.D. notified Syndax Pharmaceuticals, Inc. (the "Company") of his decision to resign from the Board of Directors of the Company (the "Board") due to an increase in the scope of his role at Lupin Limited.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001564590-22-006493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.